Navigation Links
Presentation of 1-year IVAN and 2-year CATT study results

Rockville, Md.: ARVO is pleased to host a presentation of the one-year results from the U.K.'s Inhibition of VEGF in Age-related Choroidal Neovascularisation (IVAN) study and the two-year results of the Comparison of Age-related Macular Degeneration Treatments Trials (CATT) trial.

These two multicenter randomized clinical trials, sponsored by the National Institute of Health Research in the United Kingdom and the National Eye Institute, respectively, evaluate the relative efficacy and safety of Lucentis and Avastin in the management of neovascular age-related macular degeneration (AMD).

The presentation will also live-streamed at While annual meeting registration is required for the session in Fort Lauderdale, the online is event is free.

The 2012 ARVO Annual Meeting, Translational Research: Seeing the Possibilities, takes place May 6 10 in Fort Lauderdale, Fla. Registration information can be found at


Contact: Katrina Norfleet
Association for Research in Vision and Ophthalmology

Page: 1

Related medicine news :

1. 2011 AAO-HNSF poster presentations
2. Neuralstem ALS trial in multiple presentations at upcoming American Academy of Neurology meeting
3. The John Theurer Cancer Center to unveil 40 presentations at the 52nd ASH Annual Meeting
4. Choosing Representation Can Help Disability Applicants Avoid Long Lines at Social Security Offices
5. Local Chiropractor Makes Presentation at NFL Combine
6. Nurtur Launches Quarterly Webinar Series with Presentation on the Mental Health Parity and Addiction Equity Act
7. Wound Management Technologies, Inc. Announces Conference Plans and Clinical Data Presentation at Leading Diabetic Foot Conference
8. gloStream Presentation to Focus on Microsoft Platform's Critical Role in EHR Development and Patient Information Access and Portability
9. SharpLogic Announces Launch Of SpeakFlow Non-Linear Presentation Suite At
10. Great Salt Lake Chapter of National Contract Management Association Hosts Presentation on False Claims Act by Qui Tam Attorney Tim Terry
11. Georgetown researchers examine 21-year series of nipple sparing mastectomy cases and find no cancers
Post Your Comments:
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from reveals ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: